Financial Data and Key Metrics Changes - Sales for Q1 2025 were $615 million, down 3% from $633 million in Q1 2024, primarily due to an 8% increase from the Atrion acquisition offset by a 9% organic sales decrease and a 2% unfavorable currency translation [15][16] - Adjusted earnings per share were $2.06, slightly above the midpoint of guidance but a 7% decrease from the prior year adjusted earnings per share of $2.21 [20] - Gross margin was 56%, operating profit margin was 26%, and EBITDA margin was 31%, with free cash flow conversion at nearly 150% of net income [12][13] Business Line Data and Key Metrics Changes - **Industrial Precision Solutions**: Sales decreased 11% to $300 million, with an 8% organic decline and a 3% unfavorable currency impact. EBITDA was $113 million, a 10% decrease from the prior year [21][22] - **Medical and Fluid Solutions**: Sales increased 21% to $194 million, driven by the Atrion acquisition, which contributed $53 million. EBITDA was $64 million, an 8% increase from the prior year [23][25] - **Advanced Technology Solutions**: Sales decreased 11% to $121 million, with a 10% organic decline. EBITDA was $23 million, flat year-over-year, but the segment saw improved order intake [27][29] Market Data and Key Metrics Changes - Order entry rates accelerated throughout the quarter, growing double digits compared to the prior year, with backlog increasing to approximately $670 million [11][42] - The electronics business showed improvement in order intake, indicating potential recovery despite a slow start to the year [28][46] Company Strategy and Development Direction - The company is focused on integrating the Atrion acquisition and leveraging the NBS Next growth framework to enhance operational efficiencies and profitability [35][40] - Continued commitment to product innovation is evident, with new products being launched across various segments, including medical fluid components and polymer processing [39][40] - The company aims to manage costs effectively while balancing investments to support increasing order entry trends [41][63] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a challenging demand environment but expressed confidence in the company's ability to deliver strong profitability [34][62] - The outlook for Q2 2025 anticipates sales in the range of $650 million to $690 million, with adjusted earnings per share expected between $2.30 and $2.50 [42] - Management remains cautious about geopolitical and macroeconomic factors impacting the business but sees positive signs in order entry and backlog growth [62][64] Other Important Information - The Measurement & Control Solutions division has been realigned to the Advanced Technology Solutions segment, with prior year financial information revised for comparability [6][7] - The company repurchased approximately $60 million in shares and paid $45 million in dividends during the quarter, while reducing net debt by $20 million [13][32] Q&A Session Summary Question: What played out in the electronics-related business in the quarter? - Management indicated that the miss in the ATS business was largely due to timing of orders, but order entry and backlog showed strong growth [46][47] Question: When do we start to see year-on-year growth in the interventional side of the medical-related business? - Management expects to see year-on-year growth starting in Q3 and heading into Q4 as destocking trends abate [49] Question: What would organic growth have been excluding the Measurement & Control Solutions move? - Management noted that the MCS business did not significantly impact overall growth, and its contribution was not material to the total segment [55][56] Question: What are the drivers offsetting weaker sales? - Management highlighted strong operational performance and cost management as key factors that would allow the company to meet earnings commitments despite lower sales [60][62] Question: How much of the margin dilution in the medical segment was due to Atrion? - The majority of the margin dilution was attributed to the lower EBITDA margins from Atrion, while the core medical business performed in line with expectations [81][84] Question: What is the outlook for the ARAG business? - Management indicated that the ARAG business is beginning to see modest sequential improvement in order entry and backlog, with expectations for growth in the upcoming quarters [122][156]

Financial Performance - Net sales for the three months ended January 31, 2025, were $615,420, a decrease of 2.8% compared to $633,193 for the same period in 2024[107] - Gross margin for the three months ended January 31, 2025, was $335,896, representing a gross margin percentage of 54.6%, down from 55.0% in the prior year[107] - Operating profit decreased by 11.6% to $140,947 for the three months ended January 31, 2025, compared to $159,435 in the same period of 2024[107] - Net income for the three months ended January 31, 2025, was $94,652, or $1.65 per diluted share, down 13.6% from $109,572, or $1.90 per diluted share, in the prior year[114] Segment Performance - The IPS segment experienced an organic sales decrease of 8.4%, primarily due to weaker demand in polymer processing and industrial coatings[108] - The MFS segment saw an organic sales decrease of 11.2%, attributed to lower demand in medical interventional solutions[108] - The ATS segment reported a 9.6% organic sales decrease, driven by lower systems deliveries in electronics processing[108] Cash and Financing - Cash and cash equivalents increased by $14,472 during the three months ended January 31, 2025, with 78% held at foreign subsidiaries[116] - The company has a $1,150,000 unsecured multi-currency credit facility, with $280,000 outstanding on the term loan and $220,000 on the revolving credit facility as of January 31, 2025[117] Tax and Economic Conditions - The effective tax rate for the three months ended January 31, 2025, was 19.0%, compared to 21.0% for the same period in 2024[113] - The company acknowledges risks related to U.S. and international economic and political conditions, which may impact future performance[119] Forward-Looking Statements - Forward-looking statements reflect management's current expectations but involve risks and uncertainties that could lead to significant variances from anticipated results[121] - The company has not materially changed its disclosures regarding financial instruments sensitive to interest rates and foreign currency exchange rates since the last report[123]

Core Viewpoint - Nordson Corporation's first-quarter fiscal 2025 results showed a decline in earnings and revenues, missing consensus estimates, indicating challenges in key segments and overall market conditions [1][2]. Financial Performance - Adjusted earnings per share for the first quarter were $2.06, missing the Zacks Consensus Estimate of $2.08, and decreased by 6.8% year over year [1]. - Revenues totaled $615.4 million, down 2.8% from the previous year, and also missed the consensus estimate of $636 million [2]. - Organic sales declined by 9.4% year over year, with a positive impact from acquisitions of 8.4% and a negative impact from foreign currency translation of 8.4% [3]. Segment Performance - Revenues from the Industrial Precision Solutions segment were $300 million, down 11% year over year, contributing 48.8% to total revenues [4]. - Medical and Fluid Solutions revenues increased by 21.4% to $193.6 million, contributing 31.5% to total revenues, despite an organic sales decrease of 11.2% [5]. - Advanced Technology Solutions sales were $121.4 million, up 4.7% year over year, representing 19.7% of total revenues, with organic sales down 9.6% [6]. Margin and Expenses - Cost of sales decreased by 1.8% to $279.5 million, with gross profit at $335.9 million, down 3.6%, leading to a gross margin decrease of 400 basis points to 54.6% [7]. - Selling and administrative expenses rose by 3.2% to $194.9 million, while adjusted EBITDA was $188.1 million, with a margin of 30.6% [8]. Balance Sheet and Cash Flow - Cash and cash equivalents at the end of the first quarter were $130.4 million, up from $116 million at the end of fiscal 2024, while long-term debt was $2.09 billion [9]. - Net cash generated from operating activities was $159.1 million, down 7.7% year over year, with capital expenditures of $21.4 million, up 184.2% [10]. Shareholder Returns - Dividends paid out in the first quarter totaled $44.6 million, a 14.8% increase from the previous year, and share buybacks amounted to $60.1 million, significantly up from $7.4 million [11]. Outlook - For the second quarter of fiscal 2025, Nordson projects sales between $650 million and $690 million, with adjusted earnings expected to be between $2.30 and $2.50 per share [12].

1Q Fiscal 2025 Webcast February 20, 2025 NBS NEXT OWNER MINDSET WINNING TEAMS Safe Harbor Statement Click to edit title Under the Private Securities Litigation Reform Act of 1995 Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by terminology such as "may," "will," "should," "could," "expects," "anticipates," "believes," "projects," "forecasts," "outlook," "guid ...

For the quarter ended January 2025, Nordson (NDSN) reported revenue of $615.42 million, down 2.8% over the same period last year. EPS came in at $2.06, compared to $2.21 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $636.33 million, representing a surprise of -3.29%. The company delivered an EPS surprise of -0.96%, with the consensus EPS estimate being $2.08.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street ...

Core Viewpoint - Nordson reported quarterly earnings of $2.06 per share, missing the Zacks Consensus Estimate of $2.08 per share, and down from $2.21 per share a year ago, indicating an earnings surprise of -0.96% [1] - The company posted revenues of $615.42 million for the quarter, missing the Zacks Consensus Estimate by 3.29%, and down from $633.19 million year-over-year [2] Financial Performance - Over the last four quarters, Nordson has surpassed consensus EPS estimates three times [2] - The company had a previous quarter earnings expectation of $2.59 per share but reported $2.78, delivering a surprise of 7.34% [1] - The current consensus EPS estimate for the upcoming quarter is $2.41 on revenues of $686 million, and for the current fiscal year, it is $10.20 on revenues of $2.8 billion [7] Market Position - Nordson shares have increased approximately 4.9% since the beginning of the year, outperforming the S&P 500's gain of 4.2% [3] - The Zacks Rank for Nordson is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Outlook - The Manufacturing - General Industrial industry, to which Nordson belongs, is currently in the bottom 44% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Nordson's stock performance [5]

Nordson Corporation Reports First Quarter Fiscal 2025 Results and Second Quarter Guidance First Quarter Highlights: WESTLAKE, Ohio--(BUSINESS WIRE)--February 19, 2025--Nordson Corporation (Nasdaq: NDSN) today reported results for the fiscal first quarter ended January 31, 2025. Sales were $615 million, compared to the prior year's first quarter sales of $633 million. The first quarter 2025 sales included a favorable acquisition impact of 8%, offset by an organic sales decrease of 9% and unfavorable currency ...

Core Viewpoint - Nordson Corporation (NDSN) is set to release its first-quarter fiscal 2025 earnings, with a history of positive earnings surprises averaging 5.4% [1] Group 1: Earnings Expectations - The consensus estimate for NDSN's first-quarter revenues is $636.3 million, reflecting a 0.5% increase from the previous year [5] - The adjusted earnings consensus is $2.1 per share, indicating a 5.9% decrease from the year-ago quarter [6] Group 2: Segment Performance - The Industrial Precision Solutions segment is expected to benefit from increased demand in nonwoven and industrial coating product lines, particularly in the food and beverage and pharmaceutical markets [2] - The Medical and Fluid Solutions segment is projected to see revenues of $195 million, a 21.9% increase year-over-year, driven by stable demand in the biopharma market [3] Group 3: Recent Acquisitions - The acquisition of Atrion Corporation is anticipated to enhance Nordson's medical offerings in infusion and cardiovascular therapies [4] - The acquisition of ARAG Group in August 2023 is expected to strengthen Nordson's capabilities in precision dispensing technology and expand into the precision agriculture market [4] Group 4: Challenges - The Advanced Technology Solutions segment is expected to show weakness, particularly in electronics dispense and test & inspection product lines [5] - Rising costs of sales due to high input costs and exposure to adverse currency fluctuations may negatively impact margins [6]

Analysts on Wall Street project that Nordson (NDSN) will announce quarterly earnings of $2.08 per share in its forthcoming report, representing a decline of 5.9% year over year. Revenues are projected to reach $636.33 million, increasing 0.5% from the same quarter last year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Before a company annou ...

Nordson Corporation (NDSN) is poised to benefit from strong momentum in the Industrial Precision Solutions segment, driven by the solid demand for its nonwoven and industrial coating product lines. The growing demand for the company's packaging product lines across food and beverage, pharmaceutical and other consumer goods markets is driving the segment’s performance. Sales from this segment increased 6.8% year over year in fiscal 2024 (ended October 2024).Also, stable demand for fluid solutions products, p ...